NRC Health (NRC): Depreciation & Amortization
$7.62M
Year ended 2025-12-31
$8.63M
Trailing 12 months to 2026-06-30
+6.4%
10-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.62M | +26.6% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $6.02M | +2.1% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $5.90M | n/a | 2026-03-05, From 2023-01-01 |
| No annual figure between 2019-12-31 and 2023-12-31. | |||
| 2019-12-31 | $5.54M | +1.4% | 2020-03-06, From 2019-01-01 |
| 2018-12-31 | $5.46M | +19.1% | 2020-03-06, From 2018-01-01 |
| 2017-12-31 | $4.59M | +8.5% | 2020-03-06, From 2017-01-01 |
| 2016-12-31 | $4.22M | +2.8% | 2019-03-08, From 2016-01-01 |
| 2015-12-31 | $4.11M | +8.0% | 2018-03-14, From 2015-01-01 |
| 2014-12-31 | $3.80M | +1.9% | 2017-03-03, From 2014-01-01 |
| 2013-12-31 | $3.73M | -20.6% | 2016-03-04, From 2013-01-01 |
| 2012-12-31 | $4.70M | -7.2% | 2015-03-04, From 2012-01-01 |
| 2011-12-31 | $5.07M | +7.7% | 2014-03-04, From 2011-01-01 |
| 2010-12-31 | $4.70M | +22.8% | 2013-03-01, From 2010-01-01 |
| 2009-12-31 | $3.83M | n/a | 2012-03-01, From 2009-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| NRC Health (NRC) | 2025-12-31 | $7.62M | +26.6% |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | $4.34M | +0.6% |
| OmniAb, Inc. (OABI) | 2025-12-31 | $21.75M | -7.8% |
| Foxo Technologies Inc. (FOXO) | 2025-12-31 | $597.4K | -51.6% |
| bioAffinity Technologies, Inc. (BIAF) | 2025-12-31 | $504.8K | -16.6% |
| Charles River Laboratories International, Inc. (CRL) | 2025-12-27 | $403.31M | +11.5% |
| Incyte Corp (INCY) | 2025-12-31 | $93.29M | +4.5% |
| Absci Corp (ABSI) | 2025-12-31 | $11.74M | -12.3% |
| Icon PLC (ICLR) | 2025-12-31 | $383.00M | -21.6% |
Compare NRC, MXCT, OABI, FOXO side by side · Screen every company in Services-Commercial Physical & Biological Research ↗